Skip to main content

Protein Pilfered from Cancer Cells Thwarts Immune Attack

New research in mice reveals why natural killer cells, normally effective at hunting cancer, are sometimes stopped in their tracks.  

Written byDan Robitzski
| 3 min read
Artist’s rendering of multiple natural killer cells, colored light pink, attacking a purple tumor cell.
Register for free to listen to this article
Listen with Speechify
0:00
3:00

Natural killer cells, famous for their prowess at wiping out cancer and virus-infected cells, are not always effective, particularly when it comes to fighting tumors. Now, research in mice points to a possible reason: when NK cells “bite off” part of cancer cells’ membranes, they can ingest a serving of protein that renders them useless.

NK cells, also known as large granular lymphocytes, engage tumor cells in a process called trogocytosis, which involves stealing part of their target’s membrane and integrating it into their own. The new study, published today (April 13) in Science Advances, shows in mice with leukemia that this nibble sometimes comes with a side of PD-1, a protein that inhibits NK cell activity, allowing the cancer cell to escape.

When an immune cell such as an NK cell or a T cell encounters PD-1 on the surface of a cancer cell, its activity is subdued. PD-1 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • black and white image of young man in sunglasses with trees in background

    Dan is an award-winning journalist based in Los Angeles who joined The Scientist as a reporter and editor in 2021. Ironically, Dan’s undergraduate degree and brief career in neuroscience inspired him to write about research rather than conduct it, culminating in him earning a master’s degree in science journalism from New York University in 2017. In 2018, an Undark feature Dan and colleagues began at NYU on a questionable drug approval decision at the FDA won first place in the student category of the Association of Health Care Journalists' Awards for Excellence in Health Care Journalism. Now, Dan writes and edits stories on all aspects of the life sciences for the online news desk, and he oversees the “The Literature” and “Modus Operandi” sections of the monthly TS Digest and quarterly print magazine. Read more of his work at danrobitzski.com.

    View Full Profile

Related Topics

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo